Modelling resistance and reactance with heterogeneous airway narrowing in mild to severe asthma.

Can J Physiol Pharmacol

School of Biomedical Engineering, Dalhousie University, 5981 University Avenue, Halifax, NS B3H 4R2, Canada.

Published: March 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Ventilation heterogeneity is an important marker of small airway dysfunction in asthma. The frequency dependence of respiratory system resistance (Rrs) from oscillometry is used as a measure of this heterogeneity. However, this has not been quantitatively assessed or compared with other outcomes from oscillometry, including respiratory system reactance (Xrs) and the associated elastance (Ers). Here, we used a multibranch model of the human lung, including an upper airway shunt, to match previously reported respiratory mechanics in mild to severe asthma. We imposed heterogeneity by narrowing a proportion of the peripheral airways to account for patient Ers at 5 Hz, and then narrowed central airways to account for the remaining Rrs at 18 Hz. The model required >75% of the small airways to be occluded to reproduce severe asthma. While the model produced frequency dependence in Rrs, it was upward-shifted below 5 Hz compared with in-vivo results, indicating that other factors, including more distributed airway narrowing or central airway wall compliance, are required. However, Ers quantitatively reflected the imposed heterogeneity better than the frequency dependence of Rrs, independent of the frequency range for the estimation, and thus was a more robust measure of small-airway function. Thus, Ers appears to have greater potential as a clinical measure of early small-airway disease in asthma.

Download full-text PDF

Source
http://dx.doi.org/10.1139/cjpp-2014-0436DOI Listing

Publication Analysis

Top Keywords

severe asthma
12
frequency dependence
12
airway narrowing
8
mild severe
8
respiratory system
8
imposed heterogeneity
8
airways account
8
dependence rrs
8
airway
5
asthma
5

Similar Publications

Background: This study aimed to evaluate the impact of asthma severity on biventricular cardiac functions using tissue Doppler imaging (TDI), two-dimensional speckle tracking echocardiography (2D-STE), and three-dimensional speckle tracking echocardiography (3D-STE).

Methods: Sixty-three children with asthma, aged between 5 and 16 years, were enrolled in the study along with 63 matched controls. All participants underwent cardiac assessments, including TDI, 2D-STE, 3D-STE, conventional echocardiography, and pulmonary function testing with spirometry.

View Article and Find Full Text PDF

Clinical efficacy of mepolizumab and dupilumab for eosinophilic otitis media: Analysis of patient clinical characteristic.

Allergol Int

September 2025

Department of Otolaryngology/Deafness and Middle Ear Surgicenter, Tokyo Kita Medical Center, Tokyo, Japan; Department of Otolaryngology - Head and Neck Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Background: Eosinophilic otitis media (EOM) is characterized by eosinophilic infiltration of the middle ear; it is frequently associated with bronchial asthma and chronic rhinosinusitis with nasal polyposis. Although biologics have been used to treat EOM, their efficacy based on clinical characteristics remains unclear. In this study, we evaluated the effectiveness of biologics and analyzed the clinical factors that influenced outcomes.

View Article and Find Full Text PDF

[Progress on biologic therapies for severe asthma].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, G

Biologics play a critical role in the treatment of severe bronchial asthma. Both () and in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab.

View Article and Find Full Text PDF

In recent years, several biologics have been introduced into hospitals and clinics as alternatives to surgery and/or topical/oral cortisone therapy in patients with severe refractory chronic rhinosinusitis with polyps (CRSwNP). Advances in understanding the pathophysiology of CRSwNP in relation to the predominant type 2 endotype have also paved the way for understanding possible overlaps with hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). In this article, we present the biologic treatment options currently approved in Germany for the treatment of severe CRSwNP - dupilumab, omalizumab and mepolizumab - together with guidance on practical management including side effects for the indication of CRSwNP.

View Article and Find Full Text PDF

Repurposing zafirlukast confers renal protection in ischemia-reperfusion injury via suppressing macrophage METosis.

Int Immunopharmacol

September 2025

Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China; Department of Pharmacology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China; State Key Laboratory for

Tacrolimus is widely used to prevent post-transplant acute kidney injury (AKI) but causes severe toxicities (e.g., nephrotoxicity, hyperglycemia).

View Article and Find Full Text PDF